Johns Hopkins ABX Guide
Tedizolid
INDICATIONS
FDA
FDA
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms.
- Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), andEnterococcus faecalis.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 11, 2023
Citation
Dzintars, Kathryn, and Paul G Auwaerter. "Tedizolid." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540646/all/Tedizolid.
Dzintars K, Auwaerter PG. Tedizolid. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540646/all/Tedizolid. Accessed May 30, 2023.
Dzintars, K., & Auwaerter, P. G. (2023). Tedizolid. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540646/all/Tedizolid
Dzintars K, Auwaerter PG. Tedizolid [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2023 May 30]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540646/all/Tedizolid.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tedizolid
ID - 540646
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Auwaerter,Paul,M.D.
Y1 - 2023/01/11/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540646/all/Tedizolid
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
